TG Therapeutics (NKB2) AI Stock Analysis

3 Followers

TG Therapeutics

(Frankfurt:NKB2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

BRIUMVI revenue growth and adoptionSustained sequential growth and expanding new-patient starts indicate that BRIUMVI is building durable commercial traction rather than relying on a single launch period. Continued adoption, persistence, and prescriber expansion can support revenue compounding over the next several quarters.

Negative Factors

Gross-to-net pressureIncreasing rebates, government discounts, and payer concessions can reduce the net revenue captured from each BRIUMVI treatment even when demand grows. Persistent gross-to-net pressure could limit margin expansion and require greater commercial spending to preserve access and market share.

TG Therapeutics (NKB2) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.94B
Dividend Yield: ―
Average Volume (3M): 457
Price to Earnings (P/E): 88.3
Beta (1Y): 0.28
Revenue Growth: 61.37%
EPS Growth: -75.69%
Country: Germany
Employees: 399
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

TG Therapeutics Business Overview & Revenue Model

Company Description

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solution...

TG Therapeutics Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:13.95%|Next Earnings Date:Mar 02, 2027

Earnings Call SentimentPositive

The call was strongly positive, with record commercial performance, raised 2026 revenue guidance, sustained BRIUMVI clinical results, improving profitability, share repurchases, and multiple expansion opportunities across simplified IV dosing, subcutaneous administration, azer-cel, and additional indications. The company noted ongoing gross-to-net pressure, early-stage data and regulatory dependencies, but characterized the 340B exposure as limited and continued to describe its commercial and financial outlook as strong.

Positive Updates

Revenue Guidance Raised to Approximately $1 Billion

Third-quarter global revenue was approximately $260 million, including $233 million in U.S. BRIUMVI net revenue. With solid third-quarter performance and trends pointing to a strong fourth quarter, the company raised full-year 2026 global revenue guidance to approximately $1 billion.

Negative Updates

Ongoing Gross-to-Net Pressure

Management acknowledged that gross-to-net will face pressure over time from contracting, payer mix, government discounts, and other factors. The company uses price increases to help offset these discounts and keep net price as stable as possible.

Company Guidance

TG Therapeutics raised its full year global revenue guidance to $1 billion for 2026, including full-year U.S. BRIUMVI net product revenue guidance from $890 million to $905 million to a new range of $915 million to $920 million, reflecting more than $260 million for the fourth quarter; it also expects approximately $1 billion in total global revenue, including projected payments from its ex-U.S. partner. Full-year R&D and SG&A expenses, excluding stock-based comp, are expected to be in line with prior guidance of $450 million-$500 million. The company is targeting a potential approval of the consolidated IV initiation dose around mid-2027, with the impact expected to emerge in the latter part of the second half of 2027 and into 2028, while Phase III results for subcu BRIUMVI are expected around year-end or early 2027 and a potential commercial launch is targeted for 2028. The company has not given guidance for 2027 and expects minimal impact from 340B policy changes, with 340B representing maybe about 5% of its business.

TG Therapeutics Risk Analysis

TG Therapeutics disclosed 74 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

TG Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:NKB2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	79Outperform	$3.46B	121.96	14.18%	―	60.00%	―
LEGN	72Outperform	$3.95B	-1954.00	-0.02%	―	49.73%	98.75%
PTGX	72Outperform	$8.89B	26.14	42.83%	―	163.69%	574.89%
KYMR	60Neutral	$11.67B	-37.15	-22.39%	―	133.77%	-0.64%
IMVT	53Neutral	$7.39B	-14.47	-63.01%	―	―	9.82%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:NKB2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NKB2	TG Therapeutics	58.80	31.77	117.58%
PTGX	Protagonist Therapeutics Inc	134.86	51.62	62.01%
IMVT	Immunovant, Inc.	37.04	14.22	62.31%
ARQT	Arcutis Biotherapeutics Inc	28.38	5.52	24.15%
LEGN	Legend Biotech Corporation	19.54	-11.47	-36.99%
KYMR	Kymera Therapeutics, Inc.	134.84	71.21	111.91%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

TG Therapeutics AI Stock Analysis